Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...

From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...

In a phase II trial of moderate-to-severe major depressive disorder, 6 weeks of intensive treatment with psilocybin or ...

PureTech Health has obtained approval from the US Food and Drug Administration (FDA) for KarXT to treat schizophrenia in ...

After more than three decades, schizophrenia patients have a new treatment option. The US FDA has approved a drug, known as ...

The medication is the first in decades to have a different mode of action than do current drugs, achieving better symptom ...

Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...

Nine years on from securing $3.84 million for a phase I clinical trial to test the formulation, with results showing it ...

This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb ...

Warren Buffett is famous for being a value investor while Peter Lynch tended to be growth-oriented. Some investors are ...

KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually.

The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...